Picture the moment a principal investigator at one of the 90 Viti-Up sites opens the unblinding envelope in late 2024. Her patient cohort includes adolescents as young as 12, enrolled under a pediatric study plan, with repigmentation measured by a scoring tool precise enough to distinguish a 75% facial response from a 74% one. The Facial Vitiligo Area Scoring Index 75, or F-VASI 75, has been the co-primary endpoint from day one. Either the drug crosses that threshold or it does not. And in the Viti-Up program published in The Lancet, upadacitinib 15 mg daily crossed it twice.
That replication matters more than any single p-value. AbbVie ran two independent, parallel Phase 3 randomized controlled studies, Viti-Up-1 and Viti-Up-2, enrolling 614 participants across 90 global sites, with recruitment running from December 19, 2023 through October 14, 2024. Serious adverse events came in at 3.9% versus 4.0% in the placebo arm for Study 1, and 2.0% in the upadacitinib arm for Study 2, with no new safety signals identified. For a JAK inhibitor in a non-oncology, non-life-threatening dermatologic indication, that safety symmetry with placebo is the data point every regulatory affairs team at a competing sponsor will flag first.
But the real story here is not just that the drug worked. The story is how AbbVie designed the trial to preempt every question the FDA would eventually ask, and what that architecture reveals about the emerging standard of proof for systemic treatments in vitiligo.
The Regulatory Ground AbbVie Had to Break
Vitiligo spent decades without a single FDA-approved systemic treatment. The global vitiligo market sat at an estimated $2.0 billion in 2026, with non-segmental vitiligo commanding roughly 86% of disease-type market share, yet the clinical infrastructure for pivotal trials barely existed. Sponsors who tried to build it ran into foundational problems: no validated, FDA-accepted primary endpoint, no consensus on what constitutes a clinically meaningful response, and a patient population that includes children and adolescents whose inclusion triggers mandatory pediatric study plan requirements under section 505B(e) of the Federal Food, Drug, and Cosmetic Act.
The FDA’s guidance on initial pediatric study plans requires sponsors to submit an iPSP early in development, and any amendments must be negotiated with the agency before pivotal trials begin. AbbVie did not treat this as a compliance checkbox. They enrolled patients aged 12 and older, making adolescents a pre-specified sub-population rather than an afterthought, which means whatever label upadacitinib earns will have pediatric data baked in from the start. That is a deliberate regulatory positioning move, not a humanitarian gesture alone.
The endpoint architecture reflects the same forward planning. F-VASI 75 as a co-primary endpoint for facial repigmentation is a high bar. Seventy-five percent improvement in facial vitiligo scoring is not a modest signal. Pairing it with total body VASI as the second co-primary means AbbVie had to show the drug works on the face and on the rest of the body simultaneously, giving the FDA a package that addresses both the patient-visible, quality-of-life-driving lesions and the broader disease burden. This is the kind of endpoint design that comes out of extensive Type B meeting discussions, not from a first-draft protocol.
What the JAK Class Has Already Taught the FDA
To understand why Viti-Up’s design choices landed the way they did, you have to understand where the JAK inhibitor story in dermatology has been. Baricitinib, the Eli Lilly and Incyte compound marketed as Olumiant, received FDA approval on June 13, 2022, as the first systemic treatment for adult patients with severe alopecia areata. That approval was built on data from two randomized, double-blind, placebo-controlled trials, AA-1 and AA-2, in which 35% of patients on 4 mg baricitinib achieved at least 80% scalp hair coverage at week 36. The FDA learned, through that program, what a defensible primary endpoint for a JAK inhibitor in hair and skin autoimmune disease looks like.
Alopecia areata and vitiligo are not the same disease. But from a regulatory pattern recognition standpoint, both involve an autoimmune attack on a visible, socially significant body surface, both require sponsors to justify a systemic immunomodulatory mechanism in a non-life-threatening condition, and both demand the agency weigh JAK inhibitor class safety signals (infection risk, malignancy, cardiovascular events) against quality-of-life benefit. The serious adverse event rates from Viti-Up, 3.9% and 2.0% against a placebo rate of 4.0%, suggest that at the 15 mg dose in this population, the class signal did not dominate the safety profile.
That placebo-level serious adverse event rate is the number that makes upadacitinib’s regulatory path look cleaner than competitors who come after it.
The Operational Calculus Sponsors Cannot Afford to Miss
The Viti-Up design presents a template, but templates carry traps. Sponsors planning JAK inhibitor programs in dermatology who look at Viti-Up and conclude they can simply replicate the endpoint structure are missing the context that made the endpoint defensible. F-VASI 75 worked here because AbbVie had the pre-trial FDA alignment to use it as a co-primary. Without that alignment documented in meeting minutes, a competing sponsor who adopts F-VASI 75 without equivalent regulatory negotiation is building on borrowed credibility.
The adolescent inclusion strategy carries similar nuance. Running a single pivotal program that spans adults and patients as young as 12 across 90 global sites in roughly ten months of enrollment is a site selection and IRB coordination challenge that most mid-size sponsors underestimate. The iPSP negotiation timeline alone can add six to twelve months to a development plan if it is not initiated at Phase 2 completion. Any sponsor reading Viti-Up as evidence that pediatric inclusion is operationally easy has missed the infrastructure AbbVie built over years of JAK inhibitor development in immunology.
There is also the durability question the Viti-Up data leaves open. Repigmentation at the primary timepoint is a landmark, but vitiligo is a chronic, relapsing condition. The trial design measured response at a defined endpoint. What the FDA will want for labeling language about maintenance therapy, and what payers will demand before agreeing to cover a daily oral JAK inhibitor for an adolescent over years, requires extension study data that a single pivotal program cannot provide. Sponsors who move from Phase 3 into pre-NDA meetings without a well-specified extension protocol risk a Complete Response Letter asking exactly those questions.
The Precedent Under the Precedent
Look at the vitiligo pipeline as it stood before Viti-Up published. The Vitiligo Research Foundation’s drug pipeline tracker documented how sparse serious pivotal-phase investment has been in this space. Ache Laboratorios Farmaceuticos allocated $100 million to its ACH24 candidate only to have Brazil’s ANVISA request cancellation of its Phase 3 in 2016, forcing a restart at Phase 1. That story illustrates how completely the field lacked validated trial architecture: a well-funded sponsor could not get a Phase 3 across the line even in a less restrictive regulatory environment.
AbbVie did not just generate efficacy data. It generated a replicable proof of concept for how to run a global, multi-site, dual-study vitiligo program with an adolescent cohort, a validated co-primary endpoint structure, and a safety monitoring framework calibrated for JAK inhibitor class risk. The 614 participants randomized across 90 sites in under a year represent a site activation and patient identification capability that will become the benchmark against which every subsequent vitiligo IND is measured.
Return now to that investigator opening the unblinding envelope. She is not just learning whether her patients repigmented. She is participating in the construction of the regulatory and operational standard for an entire indication. The next sponsor who submits a vitiligo IND will cite Viti-Up in their protocol justification, their endpoint rationale, and their pediatric study plan. The question is whether they understand they are citing not just a trial, but a negotiated agreement between AbbVie and the FDA about what proof of efficacy in this disease is supposed to look like, and whether they have done the pre-submission work to earn the same agreement for themselves.
References
- The Lancet — “Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies”
- PubMed — Viti-Up Phase 3 primary results: enrollment, efficacy endpoints, and safety data
- MDEdge Cutis — “Unlocking the Potential of Baricitinib in Vitiligo” (baricitinib alopecia areata FDA approval, June 13, 2022)
- FDA — Guidance on Initial Pediatric Study Plans (iPSP), section 505B(e) requirements
- Vitiligo Research Foundation — Vitiligo Drug Pipeline (ACH24 Phase 3 cancellation, ANVISA, 2016)
Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.
